Ardana Bioscience Ltd. Announces Positive Preliminary Phase 2 Results For Its Novel Testosterone Cream
Edinburgh, UK: 11 September 2006: Ardana plc (LSE:ARA) today announces preliminary results of its testosterone cream in a Phase II study in hypogonadal men. A preliminary analysis of the data confirms that Ardana’s testosterone cream is effective in restoring testosterone levels to the normal range in hypogonadal men when administered as a single dose of 2.25g or 4.5g on a daily basis.